Marathon Capital Management Buys New Shares in Zoetis Inc. $ZTS

Key Points

• Marathon Capital Management bought 35,150 shares of Zoetis in the fourth quarter, a new stake valued at about $4.423 million.
• Several large funds (Nordea, Diamond Hill, Montrusco, Arrowstreet) materially increased holdings, leaving 92.8% institutional ownership of ZTS.
• Zoetis beat the quarter with $1.48 EPS vs. $1.40 expected and $2.39B revenue vs. $2.36B, set FY2026 guidance of 7.00–7.10 EPS, pays a $0.53 quarterly dividend (1.8% yield), and carries an analyst consensus of "Hold" with a $152.25 target.

Marathon Capital Management bought a new stake in Zoetis Inc. (NYSE:ZTS - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 35,150 shares of the company's stock, valued at approximately $4,423,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ZTS. Diamond Hill Capital Management Inc. purchased a new position in Zoetis in the third quarter valued at $394,010,000. Nordea Investment Management AB raised its stake in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company's stock valued at $622,222,000 after buying an additional 2,179,578 shares in the last quarter. Montrusco Bolton Investments Inc. raised its stake in Zoetis by 256.7% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 2,168,078 shares of the company's stock valued at $266,888,000 after buying an additional 1,560,314 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Zoetis by 83.4% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,697,827 shares of the company's stock valued at $394,746,000 after buying an additional 1,227,085 shares in the last quarter. Finally, Corient Private Wealth LLC raised its stake in Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company's stock valued at $400,619,000 after buying an additional 1,191,840 shares in the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ZTS has been the topic of a number of analyst reports. Leerink Partners restated a "market perform" rating on shares of Zoetis in a research note on Tuesday, March 10th. UBS Group set a $136.00 price target on Zoetis in a research note on Thursday, January 29th. Wall Street Zen upgraded Zoetis from a "hold" rating to a "buy" rating in a research note on Saturday, February 21st. Weiss Ratings cut Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Friday, March 27th. Finally, Bank of America raised their price target on Zoetis from $135.00 to $140.00 and gave the company a "neutral" rating in a research note on Friday, February 13th. Seven research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of "Hold" and a consensus price target of $152.25.

Zoetis Stock Performance

Shares of ZTS stock opened at $116.92 on Friday. The stock's 50-day moving average is $120.83 and its two-hundred day moving average is $125.53. The firm has a market cap of $49.18 billion, a price-to-earnings ratio of 19.42, a PEG ratio of 1.77 and a beta of 0.98. Zoetis Inc. has a 1 year low of $113.29 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business's quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Analysts predict that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis's dividend payout ratio (DPR) is presently 35.22%.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.